nab-paclitaxel Monotherapy followed by Cetuximab and Radiation in Cisplatin-Unsuitable Patients with Locally Advanced Head and Neck Cancer: A Single-Arm, Multicenter Phase 2 Trial
Peter Oppelt(Washington University in St. Louis), Douglas R. Adkins(Washington University in St. Louis), Ryan S. Jackson(Washington University in St. Louis), Jason T. Rich(Washington University in St. Louis), P. Neupane(University Medical Center), Jingxia Liu(Washington University in St. Louis), Mark M. Gitau(Sanford Health), Patrik Pipkorn(Washington University in St. Louis), Kevin Palka(Washington University in St. Louis), Mackenzie Daly(University of Colorado Colorado Springs), Randal C. Paniello, Wade L. Thorstad(Washington University in St. Louis), Steven Powell(Georgetown University), Hiram A. Gay(Washington University in St. Louis), W. Spanos(Sanford Health), José P. Zevallos(University of Pittsburgh Medical Center), Jessica Ley(Washington University in St. Louis)
International Journal of Radiation Oncology*Biology*Physics
March 12, 2020
Cited by 0
Related Papers
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
|The Lancet|2018|1.7k
Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2020|1.4k
Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial
|The Lancet Oncology|2013|748
Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study
|Journal of Clinical Oncology|2017|653
NCCN Guidelines Insights: Head and Neck Cancers, Version 1.2018
|Journal of the National Comprehensive Cancer Network|2018|632